JP7896215B2 - プレウロムチリンの治療的使用 - Google Patents

プレウロムチリンの治療的使用

Info

Publication number
JP7896215B2
JP7896215B2 JP2022562465A JP2022562465A JP7896215B2 JP 7896215 B2 JP7896215 B2 JP 7896215B2 JP 2022562465 A JP2022562465 A JP 2022562465A JP 2022562465 A JP2022562465 A JP 2022562465A JP 7896215 B2 JP7896215 B2 JP 7896215B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
virus
refamulin
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522644A5 (enExample
JP2023522644A (ja
Inventor
ハフナー、マイケル
パオクナー、シュザンヌ
ヴィッカ、ヴォルフガング
リーデル、ローズマリー
－ シェーンフェルト、ズリンカ イヴェジック
Original Assignee
イマージ バイオサイエンス プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イマージ バイオサイエンス プライベート リミテッド filed Critical イマージ バイオサイエンス プライベート リミテッド
Publication of JP2023522644A publication Critical patent/JP2023522644A/ja
Publication of JP2023522644A5 publication Critical patent/JP2023522644A5/ja
Priority to JP2025230606A priority Critical patent/JP2026041886A/ja
Application granted granted Critical
Publication of JP7896215B2 publication Critical patent/JP7896215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
    • C07C321/16—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022562465A 2020-04-17 2021-04-16 プレウロムチリンの治療的使用 Active JP7896215B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025230606A JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063011474P 2020-04-17 2020-04-17
EP20170072.1 2020-04-17
US63/011,474 2020-04-17
EP20170072 2020-04-17
EP20183292.0 2020-06-30
EP20183292 2020-06-30
PCT/EP2021/025140 WO2021209174A1 (en) 2020-04-17 2021-04-16 Therapeutic use of pleuromutilins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025230606A Division JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Publications (3)

Publication Number Publication Date
JP2023522644A JP2023522644A (ja) 2023-05-31
JP2023522644A5 JP2023522644A5 (enExample) 2025-07-30
JP7896215B2 true JP7896215B2 (ja) 2026-07-29

Family

ID=75801547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562465A Active JP7896215B2 (ja) 2020-04-17 2021-04-16 プレウロムチリンの治療的使用
JP2025230606A Pending JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025230606A Pending JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Country Status (9)

Country Link
US (1) US20230174472A1 (enExample)
EP (1) EP4135682B1 (enExample)
JP (2) JP7896215B2 (enExample)
CN (1) CN115443131A (enExample)
BR (1) BR112022020007A2 (enExample)
CA (1) CA3180535A1 (enExample)
IL (2) IL297268B1 (enExample)
TW (1) TW202203908A (enExample)
WO (1) WO2021209174A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475834A1 (en) 2022-02-09 2024-12-18 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia
CN119925362A (zh) * 2023-11-03 2025-05-06 阳光安津(南京)生物医药科技有限公司 一种化合物在制备用于治疗银屑病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522143A (ja) 2007-03-20 2010-07-01 ナブリヴァ セラピュティクス アクチエンゲゼルシャフト 微生物によって媒介される病気の治療のためのプレウロムチリン誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
EP1896404B1 (en) * 2005-06-27 2014-09-17 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GB0803707D0 (en) * 2008-02-28 2008-04-09 Cambridge Entpr Ltd Antiviral agent
EP2399904A1 (en) 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103242210B (zh) 2012-02-09 2014-09-24 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
PT3310331T (pt) 2015-06-17 2021-01-19 Nabriva Therapeutics GmbH Formulações farmacêuticas injetáveis de lefamulina
CN110507823B (zh) * 2019-08-20 2021-08-24 中国医学科学院基础医学研究所 衣康酸相关物质在诊断、防治病毒感染性疾病中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522143A (ja) 2007-03-20 2010-07-01 ナブリヴァ セラピュティクス アクチエンゲゼルシャフト 微生物によって媒介される病気の治療のためのプレウロムチリン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Inflammation，2010年，Vol.33, No.5，p.306-311

Also Published As

Publication number Publication date
TW202203908A (zh) 2022-02-01
IL297268A (en) 2022-12-01
EP4135682C0 (en) 2026-06-03
CN115443131A (zh) 2022-12-06
WO2021209174A1 (en) 2021-10-21
EP4135682B1 (en) 2026-06-03
IL297268B1 (en) 2026-06-01
JP2023522644A (ja) 2023-05-31
EP4135682A1 (en) 2023-02-22
BR112022020007A2 (pt) 2022-11-22
US20230174472A1 (en) 2023-06-08
IL328193A (en) 2026-07-01
JP2026041886A (ja) 2026-03-10
CA3180535A1 (en) 2021-10-21

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250521

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260512

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260616

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260619

R150 Certificate of patent or registration of utility model

Ref document number: 7896215

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150